News
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Trading Places: The gold stock that just won over Tolga Kumova as a substantial holder
Health & Biotech
Which cancer-fighting biotech will be the next Race Oncology?
Health & Biotech
The 6 ASX small cap biotechs that have more than doubled in 2020
Experts
Scopo’s health powerplays: quick vaccine hits and cheap buys
Health & Biotech
Three investors toss an ‘unsolicited’ $3m at Race Oncology
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Check up: Speeding tickets all round
News
Trading Places: Fund managers are scrambling to buy education stocks
Health & Biotech
Check up: Diarrhoea and the FDA are lifting share prices
News
Closing Bell: Today’s biggest small cap movers on the ASX
Health & Biotech
Cancer fighter Race Oncology is now a 8-bagger in the last 12 months
News
10 at 10: These ASX stocks are off and away this morning
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech